Genome-wide association and Mendelian randomization study of NT-proBNP in patients with acute coronary syndrome
Open Access
- 21 January 2016
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 25 (7) , 1447-1456
Abstract
N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a strong predictor of mortality in coronary artery disease and is widely employed as a prognostic biomarker. However, a causal relationship between NT-proBNP and clinical endpoints has not been established. We have performed a genome-wide association and Mendelian randomization study of NT-proBNP. We used a discovery set of 3740 patients from the PLATelet inhibition and patient Outcomes (PLATO) trial, which enrolled 18 624 patients with acute coronary syndrome (ACS). A further set of 5492 patients, from the same trial, was used for replication. Genetic variants at two novel loci (SLC39A8 and POC1B/GALNT4) were associated with NT-proBNP levels and replicated together with the previously known NPPB locus. The most significant SNP (rs198389, pooled P = 1.07 × 10−15) in NPPB interrupts an E-box consensus motif in the gene promoter. The association in SLC39A8 is driven by a deleterious variant (rs13107325, pooled P = 5.99 × 10−10), whereas the most significant SNP in POC1B/GALNT4 (rs11105306, pooled P = 1.02 × 10−16) is intronic. The SLC39A8 SNP was associated with higher risk of cardiovascular (CV) death (HR = 1.39, 95% CI: 1.08–1.79, P = 0.0095), but the other loci were not associated with clinical endpoints. We have identified two novel loci to be associated with NT-proBNP in patients with ACS. Only the SLC39A8 variant, but not the NPPB variant, was associated with a clinical endpoint. Due to pleotropic effects of SLC39A8, these results do not suggest that NT-proBNP levels have a direct effect on mortality in ACS patients. PLATO Clinical Trial Registration: www.clinicaltrials.gov; NCT00391872.Keywords
Funding Information
- Uppsala University, Science for Life Laboratory, Sweden (SciLifeLab)
- Swedish Research Council (80576801, 70374401)
- SNIC through Uppsala Multidisciplinary Center for Advanced Computational Science (UPPMAX) (p2012253, p2012095)
- AstraZeneca
- Swedish Heart Foundation
This publication has 51 references indexed in Scilit:
- Biomarkers in Relation to the Effects of Ticagrelor in Comparison With Clopidogrel in Non–ST-Elevation Acute Coronary Syndrome Patients Managed With or Without In-Hospital RevascularizationCirculation, 2014
- Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial FibrillationCirculation, 2012
- Biochemistry of the human B-type natriuretic peptide precursor and molecular aspects of its processingClinica Chimica Acta, 2011
- Genome-wide association analysis and fine mapping of NT-proBNP level provide novel insight into the role of the MTHFR-CLCN6-NPPA-NPPB gene clusterHuman Molecular Genetics, 2011
- Natriuretic PeptidesJACC, 2007
- Linkage disequilibrium analyses of natriuretic peptide precursor B locus reveal risk haplotype conferring high plasma BNP levelsBiochemical and Biophysical Research Communications, 2007
- Prognostic Importance of Plasma NT-Pro BNP in Chronic Heart Failure in Patients Treated with a β-blocker: Results from the Carvedilol Or Metoprolol European Trial (COMET) TrialEuropean Journal of Heart Failure, 2007
- N-Terminal Fragment of the Prohormone Brain-Type Natriuretic Peptide (NT-proBNP), Cardiovascular Events, and Mortality in Patients With Stable Coronary Heart DiseaseJAMA, 2007
- NT-proBNP in Unstable Coronary Artery Disease—Experiences from the FAST, GUSTO IV and FRISC II TrialsEuropean Journal of Heart Failure, 2004
- Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction.Circulation, 1993